Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
13 Aug 2024
13 Aug 2024
Historique:
received:
23
01
2024
accepted:
30
07
2024
medline:
14
8
2024
pubmed:
14
8
2024
entrez:
13
8
2024
Statut:
epublish
Résumé
Although HPV vaccines are highly efficacious, a notable proportion of quadrivalent vaccinees are HPV18 seronegative post-vaccination. We have investigated this findings' validity by comparing vaccine-induced antibody responses using two different immunoassays. 6558 16-17-year-old females participated in the FUTURE II (NCT00092534) and PATRICIA (NCT00122681) trials in 2002-2004. Both the quadrivalent and bivalent vaccine recipients (QVR and BVR) received three doses. Twelve-year follow-up for 648 vaccinees was conducted by the Finnish Maternity Cohort. The presence of neutralising and binding HPV antibodies was analysed via HPV pseudovirion-based neutralisation and pseudovirion-binding assays. Four percent and 14.3% of the QVRs were seronegative for neutralising and binding antibodies to HPV16 and HPV18, respectively. No BVRs were HPV16/18 seronegative post-vaccination. The antibody titres were strongly correlated between the assays, Pearson's correlation coefficient, r
Identifiants
pubmed: 39138224
doi: 10.1038/s41541-024-00941-w
pii: 10.1038/s41541-024-00941-w
doi:
Types de publication
Journal Article
Langues
eng
Pagination
146Subventions
Organisme : Stiftelsen för Strategisk Forskning (Swedish Foundation for Strategic Research)
ID : RB13-0011
Informations de copyright
© 2024. The Author(s).
Références
Schiller, J. T., Castellsagué, X. & Garland, S. M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30, F123–F138 (2012).
pubmed: 23199956
pmcid: 4636904
doi: 10.1016/j.vaccine.2012.04.108
Godi, A. et al. Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine. Vaccine 37, 2455–2462 (2019).
pubmed: 30926298
doi: 10.1016/j.vaccine.2019.03.052
Artemchuk, H. et al. Long-term Antibody Response to Human Papillomavirus Vaccines: Up to 12 Years of Follow-up in the Finnish Maternity Cohort. J. Infect. Dis. 219, 582–589 (2019).
pubmed: 30239832
doi: 10.1093/infdis/jiy545
Tsang, S. H. et al. Durability of cross-protection by different schedules of the bivalent HPV vaccine: The CVT Trial. J. Natl. Cancer Inst. 112, 1030–1037 (2020).
pubmed: 32091596
pmcid: 7566371
doi: 10.1093/jnci/djaa010
Kann, H. et al. Sustained Cross-reactive Antibody Responses After Human Papillomavirus Vaccinations: Up to 12 Years Follow-up in the Finnish Maternity Cohort. J. Infect. Dis. 223, 1992–2000 (2021).
pubmed: 33009576
doi: 10.1093/infdis/jiaa617
Mariz, F. C. et al. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials. Lancet Infect. Dis. 21, 1458–1468 (2021). [published correction appears in Lancet Infect Dis. 2021 Aug;21(8):e208].
pubmed: 34081923
doi: 10.1016/S1473-3099(20)30873-2
Lehtinen, M. et al. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III). Int J. Cancer 143, 2299–2310 (2018).
pubmed: 29845626
doi: 10.1002/ijc.31618
Villa, L. L. et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer 95, 1459–1466 (2006).
pubmed: 17117182
pmcid: 2360730
doi: 10.1038/sj.bjc.6603469
Brown, D. R. et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J. Infect. Dis. 199, 926–935 (2009).
pubmed: 19236279
doi: 10.1086/597307
Wheeler, C. M. et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 13, 100–110 (2012). [published correction appears in Lancet Oncol. 2012 Jan;13(1):e1].
pubmed: 22075170
doi: 10.1016/S1470-2045(11)70287-X
Luostarinen, T. et al. Vaccination protects against invasive HPV-associated cancers. Int J. Cancer 142, 2186–2187 (2018).
pubmed: 29280138
doi: 10.1002/ijc.31231
Lei, J. et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N. Engl. J. Med. 383, 1340–1348 (2020).
pubmed: 32997908
doi: 10.1056/NEJMoa1917338
Huh, W. K. et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet 390, 2143–2159 (2017).
pubmed: 28886907
doi: 10.1016/S0140-6736(17)31821-4
Zhu, F. C. et al. Head-to-head immunogenicity comparison of an Escherichia coli-produced 9-valent human papillomavirus vaccine and Gardasil 9 in women aged 18-26 years in China: a randomised blinded clinical trial. Lancet Infect. Dis. 23, 1313–1322 (2023).
pubmed: 37475116
doi: 10.1016/S1473-3099(23)00275-X
Sharma, H. et al. Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9-14 years versus an established quadrivalent HPV vaccine in women aged 15-26 years in India: a randomised, active-controlled, multicentre, phase 2/3 trial. Lancet Oncol. 24, 1321–1333 (2023).
pubmed: 37949086
doi: 10.1016/S1470-2045(23)00480-1
Day, P. M. et al. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 8, 260–270 (2010).
pubmed: 20833377
pmcid: 2939057
doi: 10.1016/j.chom.2010.08.003
Arroyo Mühr, L. S. et al. Head-to-Head Comparison of Bi- and Nonavalent Human Papillomavirus Vaccine-Induced Antibody Responses. J. Infect. Dis. 226, 1195–1199 (2022).
pubmed: 35535025
pmcid: 9518834
doi: 10.1093/infdis/jiac190
Watson-Jones, D. et al. Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial. Lancet Glob. Health 10, e1473–e1484 (2022).
pubmed: 36113531
pmcid: 9638030
doi: 10.1016/S2214-109X(22)00309-6
Einstein, M. H. et al. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial. Hum. Vaccin Immunother. 10, 3435–3445 (2014).
pubmed: 25483701
pmcid: 4514070
doi: 10.4161/hv.36121
Draper, E. et al. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls. PLoS One 8, e61825 (2013).
pubmed: 23650505
pmcid: 3641072
doi: 10.1371/journal.pone.0061825
Mariz, F. C. et al. Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines. NPJ Vaccines. 5, 14 (2020).
pubmed: 32128255
pmcid: 7021830
doi: 10.1038/s41541-020-0165-x
Olsson, S. E. et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25, 4931–4939 (2007).
pubmed: 17499406
doi: 10.1016/j.vaccine.2007.03.049
Kjaer, S. K. et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries. EclinicalMedicine 23, 100401 (2020).
pubmed: 32637895
pmcid: 7329692
doi: 10.1016/j.eclinm.2020.100401
Donken, R. et al. Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial. Clin. Infect. Dis. 71, 1022–1029 (2020).
pubmed: 31617568
doi: 10.1093/cid/ciz887
World Health Organisation, WHO. WHO cervical cancer elimination initiative: from call to action to global movement. 2023 https://www.who.int/publications/m/item/who-cervical-cancer-elimination-initiative--from-call-to-action-to-global-movement [accessed 8th December 2023].
World Health Organisation, WHO. SAGE April 2022 meeting highlights. 2022 https://cdn.who.int/media/docs/default-source/reproductive-health/sage_april2022meetinghighlights_11apr2022_final.pdf?sfvrsn=21bcfb4f_3 [accessed 8th December 2023].
FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J. Med. 2007;356:1915–1927.
Paavonen, J. et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369, 2161–2170 (2007). [published correction appears in Lancet. 2007 Oct 20;370(9596):1414].
pubmed: 17602732
doi: 10.1016/S0140-6736(07)60946-5
Joura, E. A. et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 26, 6844–6851 (2008).
pubmed: 18930097
doi: 10.1016/j.vaccine.2008.09.073
Stanley, M., Pinto, L. A. & Trimble, C. Human papillomavirus vaccines-immune responses. Vaccine 30, F83–F87 (2012).
pubmed: 23199968
doi: 10.1016/j.vaccine.2012.04.106
Roy, V. et al. Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination. NPJ Vaccines. 8, 39 (2023).
pubmed: 36922512
pmcid: 10017795
doi: 10.1038/s41541-023-00628-8
Ahmed, A. I., Bissett, S. L. & Beddows, S. Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines. Infect. Genet Evol. 18, 151–159 (2013).
pubmed: 23722024
pmcid: 3769806
doi: 10.1016/j.meegid.2013.05.013
Pinto, L. A., Dillner, J., Beddows, S. & Unger, E. R. Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development. Vaccine 36, 4792–4799 (2018).
pubmed: 29361344
pmcid: 6050153
doi: 10.1016/j.vaccine.2017.11.089
Petäjä, T. et al. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. Int J. Cancer 129, 2147–2157 (2011).
pubmed: 21190190
doi: 10.1002/ijc.25887
Lacey, C. J. HPV vaccination in HIV infection. Papillomavirus Res. 8, 100174 (2019).
pubmed: 31252073
pmcid: 6603434
doi: 10.1016/j.pvr.2019.100174
Joshi, S. et al. Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination. Vaccine 41, 236–245 (2023).
pubmed: 36446654
pmcid: 9792650
doi: 10.1016/j.vaccine.2022.11.044
Schiller, J. & Lowy, D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine 36, 4768–4773 (2018).
pubmed: 29325819
pmcid: 6035892
doi: 10.1016/j.vaccine.2017.12.079
Quang, C., Chung, A. W., Frazer, I. H., Toh, Z. Q. & Licciardi, P. V. Single-dose HPV vaccine immunity: is there a role for non-neutralizing antibodies? Trends Immunol. 43, 815–825 (2022).
pubmed: 35995705
doi: 10.1016/j.it.2022.07.011
Lehtinen, M., Surcel, H. M., Natunen, K., Pukkala, E. & Dillner, J. Cancer Registry follow-up for 17 million person-years of a nationwide maternity cohort. Cancer Med. 6, 3060–3064 (2017).
pubmed: 29071810
pmcid: 5727241
doi: 10.1002/cam4.1222
Faust, H., Knekt, P., Forslund, O. & Dillner, J. Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparin-coated beads. J. Gen. Virol. 91, 1840–1848 (2010).
pubmed: 20181747
doi: 10.1099/vir.0.019349-0
Eklund, C., Unger, E. R., Nardelli-Haefliger, D., Zhou, T. & Dillner, J. International collaborative proficiency study of Human Papillomavirus type 16 serology. Vaccine 30, 294–299 (2012).
pubmed: 22079074
doi: 10.1016/j.vaccine.2011.10.096
Faust, H., Eklund, C., Sukvirach, S., Ngamkham, J. & Dillner, J. Sourcing of the WHO human papillomavirus type 18 international standards for HPV antibody levels. J. Clin. Virol. 78, 89–92 (2016).
pubmed: 27002710
doi: 10.1016/j.jcv.2016.03.014
Grabowska, K., Wang, X., Jacobsson, A. & Dillner, J. Evaluation of cost-precision rations of different strategies for ELISA measurement of serum antibody levels. J. Immunol. Methods 271, 1–15 (2002).
pubmed: 12445724
doi: 10.1016/S0022-1759(02)00334-4
Sehr, P. et al. High-throughput pseudovirion-based neutralization assay for analysis of natural and vaccine-induced antibodies against human papillomaviruses. PLoS One 8, e75677 (2013).
pubmed: 24124504
pmcid: 3790823
doi: 10.1371/journal.pone.0075677